FY2026 Earnings Estimate for LENZ Issued By William Blair

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Research analysts at William Blair issued their FY2026 earnings per share estimates for LENZ Therapeutics in a report released on Thursday, March 20th. William Blair analyst L. Hanbury-Brown anticipates that the company will post earnings of ($2.89) per share for the year. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Several other analysts also recently weighed in on LENZ. Citigroup lifted their target price on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, March 20th. TD Cowen began coverage on LENZ Therapeutics in a research note on Tuesday, March 18th. They issued a "buy" rating and a $60.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, LENZ Therapeutics presently has an average rating of "Buy" and an average target price of $41.67.

Remove Ads

LENZ Therapeutics Stock Performance

Shares of LENZ Therapeutics stock traded down $0.23 on Friday, reaching $26.43. The company had a trading volume of 224,428 shares, compared to its average volume of 166,722. The firm's 50 day moving average price is $24.30 and its two-hundred day moving average price is $27.12. LENZ Therapeutics has a 52-week low of $14.42 and a 52-week high of $38.93. The firm has a market cap of $726.85 million, a PE ratio of -5.54 and a beta of 0.58.

Institutional Trading of LENZ Therapeutics

Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in LENZ Therapeutics during the 4th quarter worth about $29,000. KLP Kapitalforvaltning AS acquired a new position in shares of LENZ Therapeutics during the fourth quarter worth about $46,000. Tower Research Capital LLC TRC increased its stake in shares of LENZ Therapeutics by 162.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after buying an additional 1,151 shares during the period. Virtus ETF Advisers LLC purchased a new stake in shares of LENZ Therapeutics during the fourth quarter worth approximately $67,000. Finally, SG Americas Securities LLC raised its holdings in LENZ Therapeutics by 20.7% in the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock valued at $158,000 after acquiring an additional 935 shares in the last quarter. Hedge funds and other institutional investors own 54.32% of the company's stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.